Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$622M |
| 2 |
Alibaba
BABA
|
+$509M |
| 3 |
Goldman Sachs
GS
|
+$500M |
| 4 |
Microsoft
MSFT
|
+$365M |
| 5 |
Halliburton
HAL
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$686M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$629M |
| 3 |
Kroger
KR
|
+$617M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$545M |
| 5 |
Morgan Stanley
MS
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.67% |
| 2 | Technology | 18.06% |
| 3 | Healthcare | 16.18% |
| 4 | Communication Services | 11.92% |
| 5 | Financials | 9.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSW
476
CSW Industrials
CSW
$4.44B
| $9.8M | 0.01% |
+302,592
| New | +$9.95M |
|
|
DM
477
DELISTED
Dominion Energy Midstream Ptr LP
DM
| $9.73M | 0.01% |
407,074
-176,865
| -30% | -$4.56M |
|
|
GNMX
478
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $9.56M | 0.01% |
1,715,850
-39,185
| -2% | -$223K |
|
479
Corvus Pharmaceuticals
CRVS
$1.1B
| $9.37M | 0.01% |
569,327
-1,154
| -0.2% | -$16.6K |
|
480
Spyre Therapeutics
SYRE
$8.5B
| $9.13M | 0.01% |
56,998
+1,475
| +3% | +$205K |
|
481
Agios Pharmaceuticals
AGIO
$2.08B
| $8.94M | 0.01% |
169,252
-722
| -0.4% | -$31.4K |
|
|
ZEN
482
DELISTED
ZENDESK INC
ZEN
| $8.78M | 0.01% |
285,867
-22,844
| -7% | -$679K |
|
|
NBLX
483
DELISTED
Noble Midstream Partners LP
NBLX
| $8.43M | 0.01% |
+302,238
| New | +$8.14M |
|
484
Marcus & Millichap
MMI
$1.2B
| $8.42M | 0.01% |
322,001
-41,305
| -11% | -$1.09M |
|
485
MPLX
MPLX
$58.6B
| $8.4M | 0.01% |
247,966
+71,936
| +41% | +$2.37M |
|
|
MPG
486
DELISTED
Metaldyne Performance Group Inc.
MPG
| $8.13M | 0.01% |
513,123
-114,883
| -18% | -$1.79M |
|
|
FL
487
DELISTED
Foot Locker
FL
| $8.02M | 0.01% |
+118,462
| New | +$7.39M |
|
|
DCOY
488
Decoy Therapeutics
DCOY
$2.14M
| $7.99M | 0.01% |
1
| – | – |
|
489
Chemours
CC
$2.48B
| $7.9M | 0.01% |
+493,645
| New | +$5.64M |
|
|
CORE
490
DELISTED
Core Mark Holding Co., Inc.
CORE
| $7.66M | 0.01% |
+213,823
| New | +$9.21M |
|
|
AVXS
491
DELISTED
AveXis, Inc. Common Stock
AVXS
| $7.55M | 0.01% |
183,145
+3,362
| +2% | +$128K |
|
|
FENX
492
DELISTED
Fenix Parts, Inc.
FENX
| $7.16M | 0.01% |
1,807,324
-169,647
| -9% | -$719K |
|
|
CMRX
493
DELISTED
Chimerix, Inc.
CMRX
| $7.07M | 0.01% |
1,276,937
-5,667
| -0.4% | -$25.9K |
|
494
Jazz Pharmaceuticals
JAZZ
$16.1B
| $6.92M | 0.01% |
56,937
-549,083
| -91% | -$74M |
|
495
USA Compression Partners
USAC
$3.69B
| $6.9M | 0.01% |
367,189
+6,888
| +2% | +$110K |
|
496
Energy Transfer Partners
ET
$69.5B
| $6.67M | 0.01% |
+397,234
| New | +$6.71M |
|
|
DSCI
497
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $6.58M | 0.01% |
1,409,668
-3,866
| -0.3% | -$18K |
|
|
KITE
498
DELISTED
Kite Pharma, Inc.
KITE
| $6.42M | 0.01% |
+114,879
| New | +$6.4M |
|
499
Exelixis
EXEL
$13.9B
| $6.39M | 0.01% |
+500,000
| New | +$5.41M |
|
500
CALL
Biogen
BIIB
$30.9B
| $6.26M | 0.01% |
+20,000
| New | +$5.92M |
|
Similar funds
Jennison Associates's Q3 2016 Portfolio in Review
As of Q3 2016, Jennison Associates held 716 positions worth $92.8B, up 1.8% from $91.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jennison Associates withdrew a net $3.95B in Q3 2016, closing 67 positions and reducing 379 holdings. Its most notable exit was IHS INC CL-A COM STK, an estimated $131M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Jennison Associates opened a new position in FedEx worth $216M.
- Jennison Associates's largest Q3 2016 buy was FedEx: 1,233,863 shares worth $216M.
- Jennison Associates added most to Qualcomm in Q3 2016, an estimated $622M increase.
- Jennison Associates's biggest Q3 2016 reduction was Walt Disney, cutting an estimated $686M.
- Jennison Associates fully exited IHS INC CL-A COM STK in Q3 2016, selling an estimated $131M.
- Jennison Associates's ten largest holdings make up 25% of its $92.8B portfolio in Q3 2016.
- Jennison Associates opened 86 new positions and closed 67 in Q3 2016.
- Jennison Associates's portfolio value rose 1.8% quarter-over-quarter to $92.8B.
Based on Jennison Associates's 13F filing for Q3 2016, filed 1 Nov 2016.